G. Hatemi Et Al. , "Significant delay in the progression to dialysis/ESIRD for AA amyloidosis patients treated with eprodisate (NC-503): 3 years of follow-up," ZEITSCHRIFT FUR RHEUMATOLOGIE , vol.66, pp.48, 2007
Hatemi, G. Et Al. 2007. Significant delay in the progression to dialysis/ESIRD for AA amyloidosis patients treated with eprodisate (NC-503): 3 years of follow-up. ZEITSCHRIFT FUR RHEUMATOLOGIE , vol.66 , 48.
Hatemi, G., Ozdogan, H., Hazenberg, B., Gul, A., Puechal, V., Merlini, G., ... Lachmann, H.(2007). Significant delay in the progression to dialysis/ESIRD for AA amyloidosis patients treated with eprodisate (NC-503): 3 years of follow-up. ZEITSCHRIFT FUR RHEUMATOLOGIE , vol.66, 48.
Hatemi, G. Et Al. "Significant delay in the progression to dialysis/ESIRD for AA amyloidosis patients treated with eprodisate (NC-503): 3 years of follow-up," ZEITSCHRIFT FUR RHEUMATOLOGIE , vol.66, 48, 2007
Hatemi, G. Et Al. "Significant delay in the progression to dialysis/ESIRD for AA amyloidosis patients treated with eprodisate (NC-503): 3 years of follow-up." ZEITSCHRIFT FUR RHEUMATOLOGIE , vol.66, pp.48, 2007
Hatemi, G. Et Al. (2007) . "Significant delay in the progression to dialysis/ESIRD for AA amyloidosis patients treated with eprodisate (NC-503): 3 years of follow-up." ZEITSCHRIFT FUR RHEUMATOLOGIE , vol.66, p.48.
@article{article, author={G. Hatemi Et Al. }, title={Significant delay in the progression to dialysis/ESIRD for AA amyloidosis patients treated with eprodisate (NC-503): 3 years of follow-up}, journal={ZEITSCHRIFT FUR RHEUMATOLOGIE}, year=2007, pages={48} }